Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 30
Filtrar
Mais filtros

País/Região como assunto
País de afiliação
Intervalo de ano de publicação
1.
BMC Geriatr ; 24(1): 25, 2024 01 05.
Artigo em Inglês | MEDLINE | ID: mdl-38182982

RESUMO

BACKGROUND: Although dementia has emerged as an important risk factor for severe SARS-CoV-2 infection, results on COVID-19-related complications and mortality are not consistent. We examined the clinical presentations and outcomes of COVID-19 in a multicentre cohort of in-hospital patients, comparing those with and without dementia. METHODS: This retrospective observational study comprises COVID-19 laboratory-confirmed patients aged ≥ 60 years admitted to 38 hospitals from 19 cities in Brazil. Data were obtained from electronic hospital records. A propensity score analysis was used to match patients with and without dementia (up to 3:1) according to age, sex, comorbidities, year, and hospital of admission. Our primary outcome was in-hospital mortality. We also assessed admission to the intensive care unit (ICU), invasive mechanical ventilation (IMV), kidney replacement therapy (KRT), sepsis, nosocomial infection, and thromboembolic events. RESULTS: Among 1,556 patients included in the study, 405 (4.5%) had a diagnosis of dementia and 1,151 were matched controls. When compared to matched controls, patients with dementia had a lower frequency of dyspnoea, cough, myalgia, headache, ageusia, and anosmia; and higher frequency of fever and delirium. They also had a lower frequency of ICU admission (32.7% vs. 47.1%, p < 0.001) and shorter ICU length of stay (7 vs. 9 days, p < 0.026), and a lower frequency of sepsis (17% vs. 24%, p = 0.005), KRT (6.4% vs. 13%, p < 0.001), and IVM (4.6% vs. 9.8%, p = 0.002). There were no differences in hospital mortality between groups. CONCLUSION: Clinical manifestations of COVID-19 differ between older inpatients with and without dementia. We observed that dementia alone could not explain the higher short-term mortality following severe COVID-19. Therefore, clinicians should consider other risk factors such as acute morbidity severity and baseline frailty when evaluating the prognosis of older adults with dementia hospitalised with COVID-19.


Assuntos
COVID-19 , Demência , Sepse , Humanos , Idoso , Brasil/epidemiologia , Estudos de Coortes , COVID-19/complicações , COVID-19/diagnóstico , COVID-19/epidemiologia , SARS-CoV-2 , Pacientes Internados , Demência/diagnóstico , Demência/epidemiologia , Demência/terapia
2.
BMC Nephrol ; 24(1): 292, 2023 10 04.
Artigo em Inglês | MEDLINE | ID: mdl-37794354

RESUMO

BACKGROUND: Acute kidney injury has been described as a common complication in patients hospitalized with COVID-19, which may lead to the need for kidney replacement therapy (KRT) in its most severe forms. Our group developed and validated the MMCD score in Brazilian COVID-19 patients to predict KRT, which showed excellent performance using data from 2020. This study aimed to validate the MMCD score in a large cohort of patients hospitalized with COVID-19 in a different pandemic phase and assess its performance to predict in-hospital mortality. METHODS: This study is part of the "Brazilian COVID-19 Registry", a retrospective observational cohort of consecutive patients hospitalized for laboratory-confirmed COVID-19 in 25 Brazilian hospitals between March 2021 and August 2022. The primary outcome was KRT during hospitalization and the secondary was in-hospital mortality. We also searched literature for other prediction models for KRT, to assess the results in our database. Performance was assessed using area under the receiving operator characteristic curve (AUROC) and the Brier score. RESULTS: A total of 9422 patients were included, 53.8% were men, with a median age of 59 (IQR 48-70) years old. The incidence of KRT was 8.8% and in-hospital mortality was 18.1%. The MMCD score had excellent discrimination and overall performance to predict KRT (AUROC: 0.916 [95% CI 0.909-0.924]; Brier score = 0.057). Despite the excellent discrimination and overall performance (AUROC: 0.922 [95% CI 0.914-0.929]; Brier score = 0.100), the calibration was not satisfactory concerning in-hospital mortality. A random forest model was applied in the database, with inferior performance to predict KRT requirement (AUROC: 0.71 [95% CI 0.69-0.73]). CONCLUSION: The MMCD score is not appropriate for in-hospital mortality but demonstrates an excellent predictive ability to predict KRT in COVID-19 patients. The instrument is low cost, objective, fast and accurate, and can contribute to supporting clinical decisions in the efficient allocation of assistance resources in patients with COVID-19.


Assuntos
COVID-19 , Masculino , Humanos , Pessoa de Meia-Idade , Idoso , Feminino , Mortalidade Hospitalar , Estudos Retrospectivos , Terapia de Substituição Renal
3.
Arch Sex Behav ; 51(5): 2603-2611, 2022 07.
Artigo em Inglês | MEDLINE | ID: mdl-35039983

RESUMO

Tenofovir/emtricitabine (TDF/FTC) has been used as pre-exposure prophylaxis (PrEP) in preventing HIV infection. PrEP is an effective prevention tool as demonstrated in clinical trials and studies in clinical practice and was incorporated into the Brazilian public health system in December 2017. The present study was a prospective cohort that included 219 PrEP users monitored over a 10 month follow-up period in a capital city in Northeastern Brazil. Data were collected from the PrEP users' electronic medical records platform made available by the Brazilian Health Ministry. During the observation period, there was good user retention to the prevention program (84%) and there was high adherence to medication (90%). Almost half the users (49%) presented an adverse event, although these were mild and transient, 30 days after starting prophylaxis. There was a significant reduction in creatinine clearance (p < .001), from 104.9 to 83.5 mL/min; however, there was no need for drug discontinuation. Throughout the cohort, there was no significant change in the number of sexual partners, but the use of condoms during sexual intercourse decreased (p < .001). There was a non-significant increase in the incidence of syphilis (p = .08), and there was a 50% decrease in reporting signs and symptoms of sexually transmitted infections. No cases of HIV infection were observed. PrEP proved to be an effective tool in HIV prevention, presenting few complications of adverse events.


Assuntos
Fármacos Anti-HIV , Infecções por HIV , Profilaxia Pré-Exposição , Infecções Sexualmente Transmissíveis , Fármacos Anti-HIV/efeitos adversos , Brasil , Emtricitabina/uso terapêutico , Infecções por HIV/epidemiologia , Homossexualidade Masculina , Humanos , Masculino , Estudos Prospectivos , Comportamento Sexual , Infecções Sexualmente Transmissíveis/epidemiologia , Infecções Sexualmente Transmissíveis/prevenção & controle
4.
BMC Health Serv Res ; 16: 227, 2016 07 07.
Artigo em Inglês | MEDLINE | ID: mdl-27387752

RESUMO

BACKGROUND: Many Brazilian patients with complex diseases who are treated in tertiary referral clinics have been stable for long periods. The main needs of these patients involve monitoring of risk factors and review of drug prescriptions, which could be satisfactorily done in primary care facilities. The goal of this protocol is to evaluate the safety and effectiveness of telemedicine services to support the transition of patients with stable chronic coronary artery disease from the tertiary to the primary level of care. METHODS/DESIGN: We designed a randomized non-inferiority protocol that will include 280 patients with stable coronary artery disease (for at least 12 months). Patients will be selected from the Ischemic Heart Disease Clinic in a tertiary care hospital in southern Brazil. Enrolled participants will be randomized into one of two groups: 12 months of follow-up at the same clinic; or 12 months of follow-up at a primary care facility with clinical support from a telemedicine platform including a toll-free line for physicians (intervention group). In the intervention group, decisions to refer patients to tertiary care during follow-up will be made jointly by primary physicians and medical teleconsultants. The groups will be compared in terms of the primary outcome-maintenance of baseline functional class 1 or 2 after 12 months. Secondary outcomes include control of risk factors and instability of the disease. DISCUSSION: We intend to determine the effectiveness of using telemedicine to qualify the transition of patients with chronic coronary disease from the tertiary to the primary level of care. This should facilitate the access of patients to the healthcare system, since care will be provided closer to their homes, and provide more opportunities for treatment of severe cases at tertiary care hospitals that are often overcrowded. TRIAL REGISTRATION: ClinicalTrials.gov # NCT02489565 - trial registration date May 13, 2015.


Assuntos
Doença da Artéria Coronariana/terapia , Atenção Primária à Saúde , Telemedicina , Centros de Atenção Terciária , Brasil , Doença Crônica , Feminino , Humanos , Masculino , Encaminhamento e Consulta , Projetos de Pesquisa , Fatores de Risco , Telemedicina/métodos , Cuidado Transicional
5.
Rev Bras Med Trab ; 22(1): e2022962, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-39165536

RESUMO

Introduction: Absenteeism of health workers is important because it interferes with the quality of care provided to patients. Objectives: To characterize the absenteeism-illness of workers in the municipal public health network in Chapecó, SC, Brazil (2015-2018) and test the association of two or more absences in the year with the study variables. Methods: A crosssectional study was conducted, and the variables studied were sex; age group; professional category; acting time; International Classification of Diseases and Related Health Problems, and sick leave. Descriptive analysis were performed, the factors associated with the outcome were tested, and the prevalence ratios were calculated with their respective 95% confidence intervals using Poisson regression. Results: A total of 1,695 professionals on sick leave were identified, with a higher prevalence of women (89.40%), in the 30-39 age group (33.41%), the majority with one sick leave per year (61.24%), from 3 to 9 days (47.67%). Community health workers were the category that most frequently had sick leaves (27.15%). In the years studied, there were 2,795 sick leaves (657 employees with more than one sick leaves). Musculoskeletal disorders were the main causes (21.80%) and the highest prevalence was dorsopathies (57.60%). Working for 21 years or more had a 49% higher prevalence ratio for two or more sick leaves per year, compared to having been working for up to 5 years. Conclusions: The study allowed us to characterize absenteeism-illness among workers in the healthcare services in Chapecó, SC. The results may constitute indicators of human resource management and foster strategies to promote healthy environments, prevention of diseases and injuries, and rehabilitation.


Introdução: O absenteísmo de trabalhadores da saúde é importante por interferir na qualidade da assistência prestada aos pacientes. Objetivos: Caracterizar o absenteísmo-doença dos trabalhadores da rede pública municipal de saúde de Chapecó, no estado de Santa Catarina, no período de 2015 a 2018 e testar a associação de dois ou mais afastamentos no ano com as variáveis de estudo. Métodos: Foi realizado um estudo transversal, e as variáveis estudadas foram sexo, faixa etária, categoria profissional, tempo de atuação, Classificação Internacional de Doenças e tempo de afastamento. Foram realizadas análises descritivas, testados os fatores associados ao desfecho e calculadas as razões de prevalência com os respectivos intervalos de confiança de 95% por meio da regressão de Poisson. Resultados: Foram identificados 1.695 profissionais afastados por doença, com maior prevalência do sexo feminino (89,40%), na faixa de 30 a 39 anos (33,41%), e a maioria apresentou um afastamento ao ano (61,24%), de 3 a 9 dias (47,67%). Os agentes comunitários de saúde foram a categoria com mais afastamentos (27,15%). Nos anos estudados, houve 2.795 afastamentos (657 servidores com mais de um afastamento). As doenças osteomusculares foram as principais causas identificadas (21,80%), com maior prevalência de dorsopatias (57,60%). Atuar há 21 anos ou mais apresentou razão de prevalência 49% maior para dois ou mais afastamentos no ano em comparação a estar atuando por até 5 anos. Conclusões: O estudo permitiu caracterizar o absenteísmo-doença entre trabalhadores da rede municipal de saúde de Chapecó. Os resultados encontrados poderão constituirse como indicadores de gestão de recursos humanos e fomentar estratégias de promoção de ambientes saudáveis, prevenção de doenças e agravos e reabilitação.

6.
Respir Med ; 227: 107635, 2024 06.
Artigo em Inglês | MEDLINE | ID: mdl-38641122

RESUMO

PURPOSE: To develop a mortality risk score for COVID-19 patients admitted to intensive care units (ICU), and to compare it with other existing scores. MATERIALS AND METHODS: This retrospective observational study included consecutive adult patients with laboratory-confirmed COVID-19 admitted to ICUs of 18 hospitals from nine Brazilian cities, from September 2021 to July 2022. Potential predictors were selected based on the literature review. Generalized Additive Models were used to examine outcomes and predictors. LASSO regression was used to derive the mortality score. RESULTS: From 558 patients, median age was 69 years (IQR 58-78), 56.3 % were men, 19.7 % required mechanical ventilation (MV), and 44.8 % died. The final model comprised six variables: age, pO2/FiO2, respiratory function (respiratory rate or if in MV), chronic obstructive pulmonary disease, and obesity. The AB2CO had an AUROC of 0.781 (95 % CI 0.744 to 0.819), good overall performance (Brier score = 0.191) and an excellent calibration (slope = 1.063, intercept = 0.015, p-value = 0.834). The model was compared with other scores and displayed better discrimination ability than the majority of them. CONCLUSIONS: The AB2CO score is a fast and easy tool to be used upon ICU admission.


Assuntos
COVID-19 , Unidades de Terapia Intensiva , Respiração Artificial , Humanos , Masculino , COVID-19/epidemiologia , Idoso , Estudos Retrospectivos , Feminino , Pessoa de Meia-Idade , Unidades de Terapia Intensiva/estatística & dados numéricos , Respiração Artificial/estatística & dados numéricos , Brasil/epidemiologia , Doença Pulmonar Obstrutiva Crônica/fisiopatologia , Doença Pulmonar Obstrutiva Crônica/terapia , Medição de Risco/métodos , Mortalidade Hospitalar , Obesidade/complicações , Fatores de Risco , Fatores Etários
7.
Cien Saude Colet ; 28(6): 1819-1830, 2023 Jun.
Artigo em Português, Inglês | MEDLINE | ID: mdl-37255158

RESUMO

The aim of this study was to evaluate the effectiveness in a real-world study of adjuvant trastuzumab in women with HER-2+ initial breast cancer in overall survival and recurrence-free survival. A retrospective cohort study was conducted with women who had HER-2+ breast cancer treated with trastuzumab from July 2012 to May 2017 and followed up until July 2021. The death rate was 2.62 per 100 persons/year, and the incidence rate of recurrence was 7.52 per 100 persons/year. The probability of survival at 8.7 years was 85.9%, while the probability of recurrence-free survival in the same period was 62.8%. The use of trastuzumab proved to be effective in the adjuvant treatment of breast cancer in a public health service in southern Brazil. Prognostic factors associated with worse overall survival or relapse did not influence the natural history of the disease, except locally advanced disease at the beginning of treatment. The data presented may prove to be useful in helping to make decisions about whether to use trastuzumab in the treatment of initial or locally advanced breast cancer in the Brazilian SUS.


O objetivo deste artigo é avaliar a efetividade em estudo de vida real do trastuzumabe adjuvante em mulheres com câncer de mama inicial HER-2 positivo na sobrevida global e livre de recidiva. Foi realizado um estudo de coorte retrospectiva em mulheres com câncer de mama inicial HER-2 positivo atendidas no SUS, desde a incorporação da medicação. Trata-se de uma coorte retrospectiva com mulheres com câncer de mama HER-2 positivo, que foram tratadas entre julho de 2012 e maio de 2017 com seguimento até julho de 2021. A taxa de incidência de óbito foi de 2,62 por 100 pessoa/ano e a de recidiva foi de 7,52 por 100 pessoa/ano. A probabilidade de sobrevida em 8,7 anos foi 85,9%, enquanto a probabilidade de sobrevida livre de doença no mesmo período foi 62,8%. O uso de trastuzumabe se mostrou efetivo no tratamento adjuvante do câncer de mama em um serviço público de saúde no Sul do Brasil. Fatores prognósticos associados com pior sobrevida ou recidiva não influenciaram na história natural da doença, exceto doença localmente avançada no início do tratamento. Os dados apresentados podem vir a ser úteis em auxiliar na tomada de decisão sobre a manutenção ou não do uso do trastuzumabe no tratamento do câncer de mama inicial ou localmente avançado no serviço público de saúde brasileiro.


Assuntos
Neoplasias da Mama , Humanos , Feminino , Trastuzumab/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Estudos Retrospectivos , Anticorpos Monoclonais Humanizados , Recidiva Local de Neoplasia/epidemiologia
8.
Arq Bras Cardiol ; 120(9): e20220935, 2023 09.
Artigo em Inglês, Português | MEDLINE | ID: mdl-37878893

RESUMO

BACKGROUND: Despite no evidence showing benefits of hydroxychloroquine and chloroquine with or without azithromycin for COVID-19 treatment, these medications have been largely prescribed in Brazil. OBJECTIVES: To assess outcomes, including in-hospital mortality, electrocardiographic abnormalities, hospital length-of-stay, admission to the intensive care unit, and need for dialysis and mechanical ventilation, in hospitalized COVID-19 patients who received chloroquine or hydroxychloroquine, and to compare outcomes between those patients and their matched controls. METHODS: A retrospective multicenter cohort study that included consecutive laboratory-confirmed COVID-19 patients from 37 Brazilian hospitals from March to September 2020. Propensity score was used to select matching controls by age, sex, cardiovascular comorbidities, and in-hospital use of corticosteroid. A p-value <0.05 was considered statistically significant. RESULTS: From 7,850 COVID-19 patients, 673 (8.6%) received hydroxychloroquine and 67 (0.9%) chloroquine. The median age in the study group was 60 years (46 - 71) and 59.1% were women. During hospitalization, 3.2% of patients presented side effects and 2.2% required therapy discontinuation. Electrocardiographic abnormalities were more prevalent in the chloroquine/hydroxychloroquine group (13.2% vs. 8.2%, p=0.01), and the long corrected QT interval was the main difference (3.6% vs. 0.4%, p<0.001). The median hospital length of stay was longer in the HCQ/CQ + AZT group than in controls (9.0 [5.0, 18.0] vs. 8.0 [4.0, 14.0] days). There was no statistical differences between groups in intensive care unit admission (35.1% vs. 32.0%; p=0.282), invasive mechanical ventilation support (27.0% vs. 22.3%; p=0.074) or mortality (18.9% vs. 18.0%; p=0.682). CONCLUSION: COVID-19 patients treated with chloroquine or hydroxychloroquine had a longer hospital length of stay, when compared to matched controls. Intensive care unit admission, invasive mechanical ventilation, dialysis and in-hospital mortality were similar.


FUNDAMENTO: Apesar da ausência de evidência mostrando benefícios da hidroxicloroquina e da cloroquina combinadas ou não à azitromicina no tratamento da covid-19, esses medicamentos têm sido amplamente prescritos no Brasil. OBJETIVOS: Avaliar desfechos, incluindo moralidade hospitalar, alterações eletrocardiográficas, tempo de internação, admissão na unidade de terapia intensiva, e necessidade de diálise e de ventilação mecânica em pacientes hospitalizados com covid-19 que receberam cloroquina ou hidroxicloroquina, e comparar os desfechos entre aqueles pacientes e seus controles pareados. MÉTODOS: Estudo multicêntrico retrospectivo do tipo coorte que incluiu pacientes com diagnóstico laboratorial de covid-19 de 37 hospitais no Brasil de março a setembro de 2020. Escore de propensão foi usado para selecionar controles pareados quanto a idade, sexo, comorbidades cardiovasculares, e uso de corticosteroides durante a internação. Um valor de p<0,05 foi considerado estatisticamente significativo. RESULTADOS: Dos 7850 pacientes com covid-19, 673 (8,6%) receberam hidroxicloroquina e 67 (0,9%) cloroquina. A idade mediana no grupo de estudo foi 60 (46-71) anos e 59,1% eram mulheres. Durante a internação, 3,2% dos pacientes apresentaram efeitos adversos e 2,2% necessitaram de interromper o tratamento. Alterações eletrocardiográficas foram mais prevalentes no grupo hidroxicloroquina/cloroquina (13,2% vs. 8,2%, p=0,01), e o prolongamento do intervalo QT corrigido foi a principal diferença (3,6% vs. 0,4%, p<0,001). O tempo mediano de internação hospitalar foi maior no grupo usando CQ/HCQ em relação aos controles (9,0 [5,0-18,0] vs. 8,0 [4,0-14,0] dias). Não houve diferenças estatisticamente significativas entre os grupos quanto a admissão na unidade de terapia intensiva (35,1% vs. 32,0%; p=0,282), ventilação mecânica invasiva (27,0% vs. 22,3%; p=0,074) ou mortalidade (18,9% vs. 18,0%; p=0,682). CONCLUSÃO: Pacientes com covid-19 tratados com cloroquina ou hidroxicloroquina apresentaram maior tempo de internação hospitalar, em comparação aos controles. Não houve diferença em relação a admissão em unidade de terapia intensiva, necessidade de ventilação mecânica e mortalidade hospitalar.


Assuntos
Tratamento Farmacológico da COVID-19 , Cloroquina , Hidroxicloroquina , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Arritmias Cardíacas/tratamento farmacológico , Azitromicina/uso terapêutico , Brasil/epidemiologia , Cloroquina/efeitos adversos , Estudos de Coortes , COVID-19 , Hidroxicloroquina/efeitos adversos , Estudos Retrospectivos , SARS-CoV-2
9.
Sci Rep ; 13(1): 3463, 2023 03 01.
Artigo em Inglês | MEDLINE | ID: mdl-36859446

RESUMO

The majority of early prediction scores and methods to predict COVID-19 mortality are bound by methodological flaws and technological limitations (e.g., the use of a single prediction model). Our aim is to provide a thorough comparative study that tackles those methodological issues, considering multiple techniques to build mortality prediction models, including modern machine learning (neural) algorithms and traditional statistical techniques, as well as meta-learning (ensemble) approaches. This study used a dataset from a multicenter cohort of 10,897 adult Brazilian COVID-19 patients, admitted from March/2020 to November/2021, including patients [median age 60 (interquartile range 48-71), 46% women]. We also proposed new original population-based meta-features that have not been devised in the literature. Stacking has shown to achieve the best results reported in the literature for the death prediction task, improving over previous state-of-the-art by more than 46% in Recall for predicting death, with AUROC 0.826 and MacroF1 of 65.4%. The newly proposed meta-features were highly discriminative of death, but fell short in producing large improvements in final prediction performance, demonstrating that we are possibly on the limits of the prediction capabilities that can be achieved with the current set of ML techniques and (meta-)features. Finally, we investigated how the trained models perform on different hospitals, showing that there are indeed large differences in classifier performance between different hospitals, further making the case that errors are produced by factors that cannot be modeled with the current predictors.


Assuntos
COVID-19 , Adulto , Humanos , Feminino , Pessoa de Meia-Idade , Masculino , Brasil , Hospitais , Hospitalização , Aprendizado de Máquina
10.
Arq Bras Cardiol ; 120(2): e20220151, 2023.
Artigo em Inglês, Português | MEDLINE | ID: mdl-36856237

RESUMO

BACKGROUND: Cardiovascular complications of COVID-19 are important aspects of the disease's pathogenesis and prognosis. Evidence on the prognostic role of troponin and myocardial injury in Latin American hospitalized COVID-19 patients is still scarce. OBJECTIVES: To evaluate myocardial injury as independent predictor of in-hospital mortality and invasive mechanical ventilation support in hospitalized patients, from the Brazilian COVID-19 Registry. METHODS: This cohort study is a substudy of the Brazilian COVID-19 Registry, conducted in 31 Brazilian hospitals of 17 cities, March-September 2020. Primary outcomes included in-hospital mortality and invasive mechanical ventilation support. Models for the primary outcomes were estimated by Poisson regression with robust variance, with statistical significance of p<0.05. RESULTS: Of 2,925 patients (median age of 60 years [48-71], 57.1% men), 27.3% presented myocardial injury. The proportion of patients with comorbidities was higher among patients with cardiac injury (median 2 [1-2] vs. 1 [0-2]). Patients with myocardial injury had higher median levels of brain natriuretic peptide, lactate dehydrogenase, creatine phosphokinase, N-terminal pro-brain natriuretic peptide, and C-reactive protein than patients without myocardial injury. As independent predictors, C-reactive protein and platelet counts were related to the risk of death, and neutrophils and platelet counts were related to the risk of invasive mechanical ventilation support. Patients with high troponin levels presented a higher risk of death (RR 2.03, 95% CI 1.60-2.58) and invasive mechanical ventilation support (RR 1.87, 95% CI 1.57-2.23), when compared to those with normal troponin levels. CONCLUSION: Cardiac injury was an independent predictor of in-hospital mortality and the need for invasive mechanical ventilation support in hospitalized COVID-19 patients.


FUNDAMENTO: As complicações cardiovasculares da COVID-19 são aspectos importantes da patogênese e do prognóstico da doença. Evidências do papel prognóstico da troponina e da lesão miocárdica em pacientes hospitalizados com COVID-19 na América Latina são ainda escassos. OBJETIVOS: Avaliar a lesão miocárdica como preditor independente de mortalidade hospitalar e suporte ventilatório mecânico em pacientes hospitalizados, do registro brasileiro de COVID-19. MÉTODOS: Este estudo coorte é um subestudo do registro brasileiro de COVID-19, conduzido em 31 hospitais brasileiros de 17 cidades, de março a setembro de 2020. Os desfechos primários incluíram mortalidade hospitalar e suporte ventilatório mecânico invasivo. Os modelos para os desfechos primários foram estimados por regressão de Poisson com variância robusta, com significância estatística de p<0,05. RESULTADOS: Dos 2925 pacientes [idade mediana de 60 anos (48-71), 57,1%], 27,3% apresentaram lesão miocárdica. A proporção de pacientes com comorbidades foi maior nos pacientes com lesão miocárdica [mediana 2 (1-2) vs. 1 (0-20)]. Os pacientes com lesão miocárdica apresentaram maiores valores medianos de peptídeo natriurético cerebral, lactato desidrogenase, creatina fosfoquinase, N-terminal do pró-peptídeo natriurético tipo B e proteína C reativa em comparação a pacientes sem lesão miocárdica. Como fatores independentes, proteína C reativa e contagem de plaquetas foram relacionados com o risco de morte, e neutrófilos e contagem de plaquetas foram relacionados ao risco de suporte ventilatório mecânico invasivo. Os pacientes com níveis elevados de troponina apresentaram um maior risco de morte (RR 2,03, IC95% 1,60-2,58) e suporte ventilatório mecânico (RR 1,87;IC95% 1,57-2,23), em comparação àqueles com níveis de troponina normais. CONCLUSÃO: Lesão cardíaca foi um preditor independente de mortalidade hospitalar e necessidade de suporte ventilatório mecânico em pacientes hospitalizados com COVID-19.


Assuntos
COVID-19 , Traumatismos Cardíacos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Brasil/epidemiologia , Proteína C-Reativa , Estudos de Coortes , Prognóstico , Idoso
11.
eNeurologicalSci ; 28: 100419, 2022 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-35935176

RESUMO

Introduction: Neurological manifestations have been associated with a poorer prognosis in COVID-19. However, data regarding their incidence according to sex and age groups is still lacking. Methods: This retrospective multicentric cohort collected data from 39 Brazilian hospitals from 17 cities, from adult COVID-19 admitted from March 2020 to January 2022. Neurological manifestations presented at hospital admission were assessed according to incidence by sex and age group. Results: From 13,603 COVID-19 patients, median age was 60 years old and 53.0% were men. Women were more likely to present with headaches (22.4% vs. 17.7%, p < 0.001; OR 1.36, 95% confidence interval [CI] 1.22-1.52) than men and also presented a lower risk of having seizures (OR 0.43, 95% CI 0.20-0.94). Although delirium was more frequent in women (6.6% vs. 5.7%, p = 0.020), sex was not associated with delirium in the multivariable logistc regresssion analysis. Delirium, syncope and coma increased with age (1.5% [18-39 years] vs. 22.4% [80 years or over], p < 0.001, OR 1.07, 95% CI 1.06-1.07; 0.7% vs. 1.7%, p = 0.002, OR 1.01, 95% CI 1.00-1.02; 0.2% vs. 1.3% p < 0.001, OR 1.04, 95% CI 1.02-1.06), while, headache (26.5% vs. 7.1%, OR 0.98, 95% CI 0.98-0.99), anosmia (11.4% vs. 3.3%, OR 0.99, 95% CI] 0.98-0.99 and ageusia (13.1% vs. 3.5%, OR 0.99, CI 0.98-0.99) decreased (p < 0.001 for all). Conclusion: Older COVID-19 patients were more likely to present delirium, syncope and coma, while the incidence of anosmia, ageusia and headaches decreased with age. Women were more likely to present headache, and less likely to present seizures.

12.
Int J Infect Dis ; 116: 319-327, 2022 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-35065257

RESUMO

BACKGROUND: It is not clear whether previous thyroid diseases influence the course and outcomes of COVID-19. METHODS: The study is a part of a multicentric cohort of patients with confirmed COVID-19 diagnosis from 37 hospitals. Matching for age, sex, number of comorbidities, and hospital was performed for the paired analysis. RESULTS: Of 7,762 patients with COVID-19, 526 had previously diagnosed hypothyroidism and 526 were matched controls. The median age was 70 years, and 68.3% were females. The prevalence of comorbidities was similar, except for coronary and chronic kidney diseases that were higher in the hypothyroidism group (p=0.015 and p=0.001). D-dimer levels were lower in patients with hypothyroid (p=0.037). In-hospital management was similar, but hospital length-of-stay (p=0.029) and mechanical ventilation requirement (p=0.006) were lower for patients with hypothyroidism. There was a trend of lower in-hospital mortality in patients with hypothyroidism (22.1% vs 27.0%; p=0.062). CONCLUSION: Patients with hypothyroidism had a lower requirement of mechanical ventilation and showed a trend of lower in-hospital mortality. Therefore, hypothyroidism does not seem to be associated with a worse prognosis.


Assuntos
COVID-19 , Hipotireoidismo , Idoso , Teste para COVID-19 , Feminino , Mortalidade Hospitalar , Humanos , Hipotireoidismo/complicações , Hipotireoidismo/epidemiologia , Prognóstico , Sistema de Registros , SARS-CoV-2
13.
J Neurol Sci ; 443: 120485, 2022 12 15.
Artigo em Inglês | MEDLINE | ID: mdl-36375382

RESUMO

BACKGROUND: Scientific data regarding the prevalence of COVID-19 neurological manifestations and prognosis in Latin America countries is still lacking. Therefore, the study aims to understand neurological manifestations of SARS-CoV 2 infection and outcomes in the Brazilian population. METHODS: This study is part of the Brazilian COVID-19 Registry, a multicentric cohort, including data from 37 hospitals. For the present analysis, patients were grouped according to the presence of reported symptoms (i.e., headache; anosmia and ageusia; syncope and dizziness) vs. clinically-diagnosed neurological manifestations (clinically-defined neurological syndrome: neurological signs or diagnoses captured by clinical evaluation) and matched with patients without neurological manifestations by age, sex, number of comorbidities, hospital of admission, and whether or not patients had underlying neurological disease. RESULTS: From 6,635 hospitalized patients with COVID-19, 30.8% presented reported neurological manifestations, 10.3% were diagnosed with a neurological syndrome and 60.1% did not show any neurological manifestations. In patients with reported symptoms, the most common ones were headache (20.7%), ageusia (11.1%) and anosmia (8.0%). In patients with neurological syndromes, acute encephalopathy was the most common diagnosis (9.7%). In the matched analysis, patients with neurological syndromes presented more cases of septic shock (17.0 vs. 13.0%, p = 0.045), intensive care unit admission (45.3 vs. 38.9%, p = 0.023), and mortality (38.7 vs. 32.6%, p = 0.026; and 39.2 vs. 30.3%, p < 0.001) when compared to controls. CONCLUSION: COVID-19 in-hospital patients with clinically defined neurological syndromes presented a higher incidence of septic shock, ICU admission and death when compared to controls.


Assuntos
Ageusia , COVID-19 , Choque Séptico , Humanos , COVID-19/complicações , COVID-19/epidemiologia , Ageusia/epidemiologia , Ageusia/etiologia , SARS-CoV-2 , Anosmia , Choque Séptico/complicações , Brasil/epidemiologia , Cefaleia/epidemiologia , Cefaleia/etiologia , Hospitais
14.
Artigo em Inglês | MEDLINE | ID: mdl-33533808

RESUMO

Respiratory syncytial virus (RSV) is the main cause of lower respiratory disease in infants and children under five years of age. As there is no specific treatment for RSV infections, prophylaxis with the specific monoclonal antibody palivizumab (PVZ) has been widely recommended for high-risk cases during the RSV season. The present study aimed to evaluate the effectiveness of a public prophylaxis program with palivizumab on the incidence of hospitalizations for lower respiratory tract infections and RSV in children at high risk for severe RSV infections. A retrospective cohort study was carried out with preterm children or children under two years of age with chronic lung disease or hemodynamically significant congenital heart disease; the children were selected on the basis of their exposure status, which was defined as the prophylactic use of palivizumab during the RSV season. Children were enrolled retrospectively in two hospitals located in Southern Brazil, from May 2009 to August 2016. In a sample of 129 children, 69 (53.5%) received palivizumab and adherence to three or more doses was observed in 78%; 60 (46.5%) children did not receive palivizumab. PVZ prophylaxis was independently associated with a 66% reduction in hospitalizations for any cause (26/69 - 37.7%) in the PVZ group and 34/60 (56.7%) in the control group). A 52% reduction in hospitalizations due to lower respiratory tract infection was observed in the PVZ group (15/69 -21.7%) and 25/60 (41.7%) in the control group. These findings suggest that, for the group of studied patients, the adoption of an RSV prophylaxis scheme reached the same effectiveness as those described in previous clinical trials.


Assuntos
Anticorpos Monoclonais Humanizados/uso terapêutico , Antivirais/uso terapêutico , Hospitalização/estatística & dados numéricos , Palivizumab/uso terapêutico , Infecções por Vírus Respiratório Sincicial/tratamento farmacológico , Brasil/epidemiologia , Criança , Pré-Escolar , Feminino , Humanos , Incidência , Lactente , Recém-Nascido , Masculino , Avaliação de Programas e Projetos de Saúde , Saúde Pública , Infecções por Vírus Respiratório Sincicial/epidemiologia , Infecções por Vírus Respiratório Sincicial/prevenção & controle , Estudos Retrospectivos
15.
PLoS One ; 15(8): e0238052, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32866163

RESUMO

The integrase inhibitor dolutegravir was included in initial antiretroviral therapy in Brazil in January 2017. Studies have demonstrated that the efficacy and safety of antiretrovirals have improved with the introduction of new classes of antiretrovirals, such as integrase inhibitors. This study aimed to estimate the frequency of individuals with a virologic response by week 24 of antiretroviral treatment and to describe the adverse events of the regimen containing dolutegravir. This was a cohort of people living with HIV followed up at a referral hospital. Patients were included who had initiated their first treatment between January and August 2017. Data were obtained from medical records, the Drug Logistics Management System and from the Laboratory Tests Control System. Two hundred and twenty-two patients were included for the tolerability analysis and one hundred and thirty-seven for the virologic response analysis. The mean age was 34 years, the median time between diagnosis and initiating treatment was 1.9 months and the median time on antiretroviral therapy was 13.2 months. The frequency of adverse events was 10% (95% CI: 7% to 15.2%), of these, amongst the most frequent events, 91% presented gastrointestinal effects, and 47.8% neuropsychiatric. By week 24 the estimated incidence of virologic response was 89.1% (95% CI: 83% to 93.5%), with an increase during the first 6 months in the number of T-CD4 lymphocytes of 50.7 cells/mm 3 (95% CI: 42 to 59.3). Initial antiretroviral regimens containing dolutegravir were well tolerated and effective in viral suppression during the first 24 weeks after initiating treatment. The occurrence of adverse events was low, either mild or moderate.


Assuntos
Fármacos Anti-HIV/efeitos adversos , Fármacos Anti-HIV/farmacologia , Infecções por HIV/tratamento farmacológico , Infecções por HIV/virologia , Compostos Heterocíclicos com 3 Anéis/efeitos adversos , Compostos Heterocíclicos com 3 Anéis/farmacologia , Segurança , Adolescente , Adulto , Idoso , Fármacos Anti-HIV/uso terapêutico , Feminino , Compostos Heterocíclicos com 3 Anéis/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Oxazinas , Piperazinas , Piridonas , Estudos Retrospectivos , Virologia
16.
Rev Bras Epidemiol ; 21: e180019, 2018 Oct 11.
Artigo em Português, Inglês | MEDLINE | ID: mdl-30328938

RESUMO

INTRODUCTION: Tuberculosis (TB) is one of the world's major public health problems. Epidemiological surveillance has proved to be an important tool to assist in the control and prevention of communicable diseases such as TB and AIDS. This study aimed to estimate the rate and factors associated with the underreporting of TB among cases of coinfection with human immunodeficiency virus (HIV)/AIDS in the state of Pernambuco, based on data from the TB and Aids Notifiable Diseases Information System (Sinan TB and Sinan AIDS). METHODS: A cross-sectional study was carried out based on the records of the TB and AIDS Notification System to identify cases of TB underreporting in the study period. In order to identify underreporting, a probabilistic linkage was undertaken using RecLink III software. RESULTS: The rate of TB underreporting was 29%, and the factors associated were: presenting a clinical form of TB as cavitary or unspecified pulmonary TB or having both kinds of TB at the same time; being treated outside the municipality of Recife; and being treated at health services not specialized for HIV/AIDS. DISCUSSION: The proportion of underreporting found in our study was lower than that observed in other Brazilian studies that took into account underreporting from mortality data. CONCLUSION: The variables associated with underreporting of TB were mostly related to the healthcare system rather than to individual characteristics, which points to the need for training of health professionals in order to notify the information systems correctly.


INTRODUÇÃO: A tuberculose (TB) é um dos graves problemas da saúde pública mundial. A vigilância epidemiológica tem se mostrado uma importante ferramenta para auxiliar em ações de controle e prevenção de doenças transmissíveis, como a TB e a aids. O objetivo do presente estudo foi estimar a proporção e os fatores associados à subnotificação da tuberculose em Pernambuco, entre os casos de coinfecção TB/aids, com base nos dados do Sistema de Informação de Agravos de Notificação da TB e da aids. MÉTODOS: Realizou-se um estudo de corte seccional, baseado nos registros dos Sistemas de Notificação de TB e aids, para identificação de casos de subnotificação de TB no período de estudo, mediante a realização de linkage probabilístico utilizando o software RecLink III. Resultados: Verificou-se proporção de 29% de subnotificação de TB, e os fatores associados à subnotificação foram: apresentar forma clínica da TB pulmonar cavitária ou não especificada, ou ter os dois tipos de TB ao mesmo tempo; e ser atendido fora do Recife e em serviços que não são especializados para vírus da imunodeficiência humana (HIV)/aids. DISCUSSÃO: A proporção de subnotificação encontrada em nosso estudo foi menor do que a observada em outras pesquisas brasileiras que levaram em consideração a subnotificação haja vista os dados de mortalidade. CONCLUSÃO: As variáveis associadas à subnotificação de TB referem-se, em sua maioria, à rede de atenção, e não às características individuais, o que aponta para a necessidade de capacitação dos profissionais de saúde para efetuar a notificação aos sistemas de informação.


Assuntos
Síndrome da Imunodeficiência Adquirida/epidemiologia , Coinfecção/epidemiologia , Sistemas de Informação/estatística & dados numéricos , Vigilância da População/métodos , Tuberculose/epidemiologia , Adulto , Brasil/epidemiologia , Estudos Transversais , Notificação de Doenças , Monitoramento Epidemiológico , Feminino , Humanos , Masculino , Registro Médico Coordenado
17.
Rev Saude Publica ; 51: 88, 2017.
Artigo em Inglês, Português | MEDLINE | ID: mdl-28954163

RESUMO

OBJECTIVE: Describe the coding process of death causes for people living with HIV/AIDS, and classify deaths as related or unrelated to immunodeficiency by applying the Coding Causes of Death in HIV (CoDe) system. METHODS: A cross-sectional study that codifies and classifies the causes of deaths occurring in a cohort of 2,372 people living with HIV/AIDS, monitored between 2007 and 2012, in two specialized HIV care services in Pernambuco. The causes of death already codified according to the International Classification of Diseases were recoded and classified as deaths related and unrelated to immunodeficiency by the CoDe system. We calculated the frequencies of the CoDe codes for the causes of death in each classification category. RESULTS: There were 315 (13%) deaths during the study period; 93 (30%) were caused by an AIDS-defining illness on the Centers for Disease Control and Prevention list. A total of 232 deaths (74%) were related to immunodeficiency after application of the CoDe. Infections were the most common cause, both related (76%) and unrelated (47%) to immunodeficiency, followed by malignancies (5%) in the first group and external causes (16%), malignancies (12 %) and cardiovascular diseases (11%) in the second group. Tuberculosis comprised 70% of the immunodeficiency-defining infections. CONCLUSIONS: Opportunistic infections and aging diseases were the most frequent causes of death, adding multiple disease burdens on health services. The CoDe system increases the probability of classifying deaths more accurately in people living with HIV/AIDS. OBJETIVO: Descrever o processo de codificação das causas de morte em pessoas vivendo com HIV/Aids, e classificar os óbitos como relacionados ou não relacionados à imunodeficiência aplicando o sistema Coding Causes of Death in HIV (CoDe). MÉTODOS: Estudo transversal, que codifica e classifica as causas dos óbitos ocorridos em uma coorte de 2.372 pessoas vivendo com HIV/Aids acompanhadas entre 2007 e 2012 em dois serviços de atendimento especializado em HIV em Pernambuco. As causas de óbito já codificadas a partir da Classificação Internacional de Doenças foram recodificadas e classificadas como óbitos relacionados e não relacionados à imunodeficiência pelo sistema CoDe. Foram calculadas as frequências dos códigos CoDe das causas do óbito em cada categoria de classificação. RESULTADOS: Ocorreram 315 (13%) óbitos no período do estudo; 93 (30%) tinham como causa uma doença definidora de Aids da lista do Centers for Disease Control and Prevention. No total 232 óbitos (74%) foram relacionados à imunodeficiência após aplicar o CoDe. As infecções foram as causas mais comuns, tanto nos óbitos relacionados (76%) como não relacionados (47%) à imunodeficiência, seguindo-se de malignidades (5%) no primeiro grupo e de causas externas (16%), malignidades (12%) e doenças cardiovasculares (11%) no segundo. A tuberculose compreendeu 70% das infecções definidoras de imunodeficiência. CONCLUSÕES: Infecções oportunistas e doenças do envelhecimento foram as causas mais frequentes de óbito, imprimindo carga múltipla de doenças aos serviços de saúde. O sistema CoDe aumenta a probabilidade de classificar os óbitos com maior precisão em pessoas vivendo com HIV/Aids.


Assuntos
Infecções Oportunistas Relacionadas com a AIDS/mortalidade , Síndrome da Imunodeficiência Adquirida/mortalidade , Causas de Morte , Codificação Clínica , Síndrome da Imunodeficiência Adquirida/complicações , Algoritmos , Brasil/epidemiologia , Estudos Transversais , Feminino , Humanos , Classificação Internacional de Doenças , Masculino
18.
Rev. enferm. UFSM ; 10: 54, 2020.
Artigo em Inglês, Português | LILACS, BDENF - enfermagem (Brasil) | ID: biblio-1123218

RESUMO

Objetivo: identificar os fatores associados à cesariana eletiva em mulheres atendidas em um hospital referência do oeste catarinense. Método: estudo transversal realizado com mulheres submetidas à cesariana. A coleta de dados ocorreu entre agosto e setembro de 2016, por meio de questionário padronizado e informações complementadas pelo prontuário e cartão pré-natal. Dados foram submetidos à regressão logística multivariada. Resultados: foram incluídas no estudo 206 mulheres. O resultado final do modelo multivariado mostrou associação de forma independente com a cesariana eletiva ter sido paga via particular ou por plano de saúde (Odds Ratio = 39,9 p<0,01) e a cor da pele autorreferida branca (Odds Ratio = 2,94 p=0,035). Conclusão: é necessário repensar a formação dos profissionais da área da saúde habilitados a atenderem gestantes, capacitando-os para o cuidado pré-natal e para o parto vaginal, visando, sobretudo, o respeito às indicações absolutas de cesarianas, especialmente nas gestantes atendidas no setor privado.


Objective: to identify factors associated with elective cesarean section in women met in a reference hospital in western Santa Catarina. Method: cross-sectional study carried out with women submitted to cesarean section. The data collection occurred between August and September 2016, through a standardized questionnaire and information complemented by the medical records and prenatal card. Data were submitted to multivariate logistic regression. Results: 206 women were included in the study. The final result of the multivariate model showed independent association with the elective cesarean section paid privately or by health insurance (Odds Ratio = 39.9 p<0.01) and self-reported skin color white (Odds Ratio = 2.94 p=0.035). Conclusion: it is necessary to rethink the training of health care professionals qualified to meet pregnant women, empowering them to prenatal care and to the vaginal delivery, aiming, above all, to respect absolute indications of cesarean sections, especially in pregnant women met in the private sector.


Objetivo: identificar los factores asociados con la cesárea electiva en mujeres atendidas en un hospital de referencia del oeste de Santa Catarina. Método: estudio transversal realizado con mujeres sometidas a cesárea. La recogida de datos se produjo entre agosto y septiembre de 2016, por medio de un cuestionario estandarizado y complementada por la información de los registros médicos y cartón prenatal. Los datos obtenidos fueron sometidos a la regresión logística multivariada. Resultados: se incluyeron 206 mujeres en el estudio. El resultado final del modelo multivariado mostró asociación independiente con la cesárea electiva ha sido pagada en privado o por un plan de salud (Odds Ratio = 39,9 p<0,01) y autorreporte del color de la piel blanco (Odds Ratio = 2,94 p=0,035). Conclusión: es necesario repensar la formación de los profesionales de atención de salud calificados para atender a las mujeres embarazadas, motivándolos a la atención prenatal y al parto vaginal, destinado, sobre todo, al respeto de las indicaciones absolutas de cesárea, especialmente en embarazadas atendidas en el sector privado.


Assuntos
Humanos , Feminino , Cesárea , Fatores de Risco , Saúde da Mulher , Saúde Suplementar , Tocologia
19.
PLoS One ; 9(4): e95828, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24755628

RESUMO

BACKGROUND: The challenge of diagnosing smear-negative pulmonary TB (tuberculosis) in people living with HIV justifies the use of instruments other than the smear test for diagnosing the disease. Considering the clinical-radiological similarities of TB amongst HIV-infected adults and children, the proposal of this study was to assess the accuracy of a scoring system used to diagnose smear-negative pulmonary TB in children and adolescents, in HIV-infected adults suspected of having smear-negative pulmonary TB. METHODS: A Phase III validation study aiming to assess the diagnostic accuracy of a scoring system for diagnosing smear-negative pulmonary TB in HIV-infected adults. The study assessed sensitivity, specificity, positive and negative likelihood ratios, and positive and negative predictive values of the scoring system. Three versions of the scoring system were tested. RESULTS: From a cohort of 2,382 (HIV-infected adults), 1276 were investigated and 128 were diagnosed with pulmonary TB. Variables associated with the diagnosis of TB were: coughing, weight loss, fever, malnutrition, chest X-ray, and positive tuberculin test. The best diagnostic performance occurred with the scoring system with new scores, with sensitivity = 81.2% (95%-CI 74.5% -88%), specificity = 78% (75.6% -80.4%), PPV = 29.2% (24.5% -33.9%) and NPV = 97.4% (96.4% -98.4%), LR+ = 3.7 (3.4-4.0) and LR- = 0.24 (0.2-0.4). CONCLUSION: The proposed scoring system (with new scores) presented a good capacity for discriminating patients who did not have pulmonary TB, in the studied population. Further studies are necessary in order to validate it, thus permitting the assessment of its use in diagnosing smear-negative pulmonary TB in HIV-infected adults.


Assuntos
Infecções por HIV/imunologia , Hospedeiro Imunocomprometido , Tuberculose Pulmonar/diagnóstico , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Mycobacterium tuberculosis/crescimento & desenvolvimento , Curva ROC , Escarro/microbiologia , Tuberculose Pulmonar/imunologia , Tuberculose Pulmonar/microbiologia
20.
Rev Inst Med Trop Sao Paulo ; 56(2): 127-32, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24626414

RESUMO

Despite the effectiveness of combination antiretroviral therapy in the treatment of people living with HIV/AIDS (PLWHA), nonadherence to medication has become a major threat to its effectiveness. This study aimed to estimate the prevalence of self-reported irregular use of antiretroviral therapy and the factors associated with such an irregularity in PLWHA. A cross-sectional study of PLWHA who attended two referral centers in the city of Recife, in Northeastern Brazil, between June 2007 and October 2009 was carried out. The study analyzed socioeconomic factors, social service support and personal habits associated with nonadherence to antiretroviral therapy, adjusted by multivariable logistic regression analysis. The prevalence of PLWHA who reported irregular use of combination antiretroviral therapy (cART) was 25.7%. In the final multivariate model, the irregular use of cART was associated with the following variables: being aged less than 40 years (OR = 1.66, 95%-CI: 1.29-2.13), current smokers (OR = 1.76, 95%-CI: 1.31-2.37) or former smokers (OR = 1.43, 95%-CI: 1.05-1.95), and crack cocaine users (OR = 2.79, 95%-CI: 1.24-6.32). Special measures should be directed towards each of the following groups: individuals aged less than 40 years, smokers, former smokers and crack cocaine users. Measures for giving up smoking and crack cocaine should be incorporated into HIV-control programs in order to promote greater adherence to antiretroviral drugs and thus improve the quality of life and prolong life expectancy.


Assuntos
Fármacos Anti-HIV/uso terapêutico , Transtornos Relacionados ao Uso de Cocaína/complicações , Cocaína Crack , Infecções por HIV/tratamento farmacológico , Adesão à Medicação/estatística & dados numéricos , Fumar/efeitos adversos , Adolescente , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Estudos Transversais , Feminino , Infecções por HIV/complicações , Humanos , Masculino , Pessoa de Meia-Idade , Fatores Socioeconômicos , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA